2013年12月31日，美国食品和药物管理局将完成其所有吸入的医疗产品中含有氟氯化碳...

清歌一曲月如霜

2013年12月31日，美国食品和药物管理局将完成其所有吸入的医疗产品中含有氟氯化碳（CFCs ）的淘汰



由2013年12月31日，美国食品和药物管理局将完成其所有吸入的医疗产品中含有氟氯化碳（CFCs ）的淘汰。这方面的努力，遵守国际条约，保护臭氧层，逐步淘汰破坏臭氧层的氟氯化碳，许多物质，包括全球范围内生产。

通过FDA虽然大多数含有氟氯化碳的吸入器产品已经被淘汰，目前两款产品仍然在市场上必特吸入气雾剂和Maxair的自动吸入药。不过，这些产品在今年年底之后将不再提供。哮喘或慢性阻塞性肺疾病（COPD）的人，谁使用这些吸入器应该跟他们的医疗保健专业替代治疗的处方。

吸入器是为那些患有哮喘或慢性阻塞性肺病的人的关键产品。在美国，超过25亿人患有哮喘，一种疾病，影响呼吸道肺部，可引起咳嗽，呼吸困难，喘息和胸闷或胸痛。此外， 15万人被诊断出患有慢性阻塞性肺病，严重的肺部疾病，随着时间的推移恶化。症状包括胸闷，慢性咳嗽，痰多。

使用氟氯化碳Badrul乔杜里说，“作为推进剂，移动药物可以使患者吸入药物吸入肺部，过敏和风湿病产品在FDA的药物评价和研究中心的科主任，医学博士， 。 “超过二十年，美国FDA和EPA合作，逐步淘汰氟氯化碳的吸入器 - 一个过程，包括公众咨询委员会，制造商，和利益相关者的投入。 ”

大多数吸入由FDA使用氟氯化碳已经被淘汰。吸入器是最广泛使用的沙丁胺醇CFC吸入器被淘汰，并在2008年取代吸入器使用的推进剂称为氢氟烷烃（ HFAS ） 。有许多安全和有效的吸入治疗哮喘和慢性阻塞性肺病的症状。所有这些吸入需要医生处方，必须来自持牌保健专业人士（医生，医生助理或护士执业） 。

EPA和FDA的合作提供了便利安全，逐步过渡到无CFC吸入器在美国， “德鲁西拉斯Hufford说，环保局的平流层保护司的空气和辐射办公室主任。 “此举是一个重要贡献的全球努力通过预防皮肤癌的修复保护地球的臭氧层，拯救数百万生命。 ”

氯氟烃会破坏臭氧层，薄，在平流层中，作为地球对太阳辐射的屏蔽外层。美国和其他大多数国家在1987年签署了一项协议，称为，全球淘汰氯氟烃的生产和使用消耗臭氧层物质的蒙特利尔议定书“ 。在美国，氯氟烃已被删除喷发胶，除臭剂和空调等产品。


The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing out the worldwide production of numerous substances, including CFCs, which contribute to ozone depletion.

While most inhaler products containing CFCs have already been phased out by the FDA, two products currently remain on the market: Combivent Inhalation Aerosol and Maxair Autohaler. However, these products will no longer be available after the end of this year. People with asthma or chronic obstructive pulmonary disease (COPD) who use these inhalers should talk to their health care professional about a prescription for an alternative treatment.

Inhalers are critical products for those persons suffering from asthma or COPD. In the United States, more than 25 million people suffer from asthma, a disease that affects the airways in the lungs and can cause coughing, trouble breathing, wheezing and tightness or pain in the chest. Additionally, 15 million people have been diagnosed with COPD, a serious lung disease that worsens over time. Symptoms can include chest tightness, chronic cough and excessive phlegm.

“CFCs were used as propellants to move the drug out of inhalers so that patients can inhale the medicine,” said Badrul Chowdhury, M.D., director of the Division of Pulmonary, Allergy and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research. “For more than two decades, the FDA and EPA have collaborated to phase-out CFCs in inhalers – a process that included input from the public, advisory committees, manufacturers, and stakeholders.”

Most inhalers that used CFCs have already been phased out by the FDA. The inhaler that was most widely used—albuterol CFC inhaler—was phased out in 2008 and replaced with inhalers that use propellants called hydrofluoroalkanes (HFAs). There are many safe and effective inhalers available to treat asthma and COPD symptoms. All of these inhalers require a prescription, which must come from a licensed health care professional (a physician, physician’s assistant or nurse practitioner).

“The EPA and FDA's partnership has facilitated a safe, gradual transition to CFC-free inhalers in the United States,” said Drusilla Hufford, director of EPA’s Stratospheric Protection Division of the Office of Air and Radiation. “This action is an important contribution to the global effort to repair the Earth’s protective ozone layer and save millions of lives through the prevention of skin cancer.”

CFCs damage the ozone layer, a thin, outer layer in the stratosphere that acts as earth's shield against the sun's radiation. The United States and most other countries signed an agreement in 1987 called the Montreal Protocol on Substances that Deplete the Ozone Layer to phase out the worldwide production and use of CFCs. In the United States, CFCs have been removed from such products as hairsprays, deodorants and air conditioning.

syhorchid

谢谢分享